Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments

Human Gene Therapy

Volumn 12, Issue 3, 2001, Pages 235-252

  Cheng, W F ^a,b   Hung, C F ^a   Hsu, K F ^a,c   Chai, C Y ^a,d   He, L ^a   Ling, M ^a   Slater, L A ^a   Roden, R B S ^a   Wu, T C ^a,e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE PROTEIN; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; DRUG POTENCY; ENDOSOME; FEMALE; FUSION GENE; GENE TARGETING; IMMUNE RESPONSE; LYSOSOME; MOUSE; NATURAL KILLER CELL; NONHUMAN; REPLICON; SINDBIS VIRUS; T LYMPHOCYTE; VIRUS REPLICATION; WART VIRUS;

ANIMALS; ANTIGENS, CD; APOPTOSIS; BONE MARROW CELLS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL MEMBRANE; CRICETINAE; DENDRITIC CELLS; DNA; ENDOSOMES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENES, MHC CLASS I; HUMANS; IN SITU NICK-END LABELING; KILLER CELLS, NATURAL; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; LYSOSOMES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; NEOPLASMS; ONCOGENE PROTEINS, VIRAL; PHAGOCYTOSIS; PLASMIDS; SINDBIS VIRUS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; TRANSFECTION; VACCINES, DNA;

ANIMALIA; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; SINDBIS VIRUS;

EID: 0035835376     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430340150218387     Document Type: Article

References (44)

1. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes
2. Dendritic cells acquire antigen from apoptotic cells and induce class Irestricted CTLs
3. Outcome of immunization of cynomolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus type 1 envelope protein and challenge with a high dose of SHIV-4 virus
4. Enhancing immune responses using suicidal DNA vaccines
5. NK cell modulation of murine cytomegalovirus retinitis
6. Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells
7. Sindbis virus expression vectors: Packaging of RNA replicons by using defective helper RNAs
8. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene
9. Identification of two lysosomal membrane glycoproteins
10. In vivo priming by DNA injection occurs predominantly by antigen transfer
11. Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: Similarity of L3T4 to the human Leu-3/T4 molecule
12. Up-regulation of NK cytotoxic activity via IL-15 induction by different viruses: A comparative study
13. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
14. Translation of Sindbis virus mRNA: Analysis of sequences downstream of the initiating AUG codon that enhance translation
15. The motif Tyr-X-X-hydrophobic residue mediates lysosomal membrane targeting of lysosome-associated membrane protein 1
16. DNA immunization against herpes simplex virus: Enhanced efficacy using a Sindbis virus-based vector
17. Cell proliferation, apoptosis, oncogene, and tumor suppressor gene status in adenosis with comparison to benign prostatic hyperplasia, prostatic intraepithelial neoplasia, and cancer
18. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses
19. Sindbis virus vectors for expression in animal cells
20. The susceptibility of mice to immune-mediated neurologic disease correlates with the degree to which their lymphocytes resist the effects of brain-derived gangliosides
21. Targeting HPV-16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine HPV-16 E7-expressing tumors
22. The NK-1.1(-) mouse: A model to study differentiation of murine NK cells
23. DNA and RNA-based vaccines: Principles, progress and prospects
24. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors
25. Glycoproteins of the lysosomal membrane
26. In vitro mutagenesis of a full-length cDNA clone of Semliki Forest virus: The small 6,000-molecular-weight membrane protein modulates virus release
27. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
28. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis
29. CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes
30. DNA tumor virus oncoproteins and retinoblastoma gene mutations share the ability to relieve the cell's requirement for cyclin D1 function in G1
31. In vitro-synthesized infectious RNA as an attenuated live vaccine in a flavivirus model
32. Characterization of the cellular and cytokine response in the central nervous system following Semliki Forest virus infection
33. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: Expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo
34. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function
35. IgG or IgM monoclonal antibodies reactive with different determinants on the molecular complex bearing Lyt 2 antigen block T cell-mediated cytolysis in the absence of complement
36. Differential tumor surveillance by natural killer (NK) and NKT cells
37. CD1-reactive natural killer T cells are required for development of systemic tolerance through an immuneprivileged site
38. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes
39. Intramuscular administration of E7-transfected dendritic cells generates the most potent E7-specific anti-tumor immunity
40. Accumulation of membrane glycoproteins in lysosomes requires a tyrosine residue at a particular position in the cytoplasmic tail
41. Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7
42. A reassessment of the role of B7-1 in anti-tumor immunity
43. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12
44. Cancer therapy using a self-replicating RNA vaccine